Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Scot Ebbinghaus

Relationship Between Immune Gene Signatures and Clinical Response to PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Advanced Solid Tumors

Journal for ImmunoTherapy of Cancer

English

Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients With Advanced Melanoma Treated With Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical Trial

European Journal of Cancer

Cancer Research

Oncology

2018

English

Related publications

Immunogenicity of Pembrolizumab in Patients With Advanced Tumors

Journal for ImmunoTherapy of Cancer

English

Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors

English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

English

O3-2-5a Phase I Trial of BI 754091, a Programmed Death Receptor 1 (PD-1) Inhibitor, in Patients With Advanced Solid Tumors

English

A Phase 1 Study of Oral Ridaforolimus in Pediatric Patients With Advanced Solid Tumors

Oncotarget

Oncology

2016

English

PD-1 Expression and Clinical PD-1 Blockade in B-Cell Lymphomas

English

P2.01-21 Antigen Cascade Triggering Correlates With Prolonged Survival in Advanced NSCLC Patients Undergone PD-1 Blockade With Nivolumab.

Journal of Thoracic Oncology

English

P1.13-32 Comparison Between Immune-Mediated Pneumonitis and Pneumonia in Patients Treated With PD-1/PD-L1 Therapy

Journal of Thoracic Oncology

English

Phase I Study of Nivolumab, an Anti-Pd-1 Antibody, in Patients With Malignant Solid Tumors

Investigational New Drugs

Oncology

Pharmacology

2016

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Scot Ebbinghaus

Relationship Between Immune Gene Signatures and Clinical Response to PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Advanced Solid Tumors

Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients With Advanced Melanoma Treated With Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical Trial

Related publications

Immunogenicity of Pembrolizumab in Patients With Advanced Tumors

Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

O3-2-5a Phase I Trial of BI 754091, a Programmed Death Receptor 1 (PD-1) Inhibitor, in Patients With Advanced Solid Tumors

A Phase 1 Study of Oral Ridaforolimus in Pediatric Patients With Advanced Solid Tumors

PD-1 Expression and Clinical PD-1 Blockade in B-Cell Lymphomas

P2.01-21 Antigen Cascade Triggering Correlates With Prolonged Survival in Advanced NSCLC Patients Undergone PD-1 Blockade With Nivolumab.

P1.13-32 Comparison Between Immune-Mediated Pneumonitis and Pneumonia in Patients Treated With PD-1/PD-L1 Therapy

Phase I Study of Nivolumab, an Anti-Pd-1 Antibody, in Patients With Malignant Solid Tumors